The FDA approved Isembyld (apitegromab-mstn) for adults and pediatric patients aged 2 years and older with spinal muscular atrophy (SMA) receiving SMN2-targeted therapy.

FDA approves Fayuvi (rebisufligene etisparvovec-hopf), the first gene therapy for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA).

Test your knowledge on recent migraine research, including pediatric adverse events and the magnitude of placebo responses.

High levels of adolescent vaccination coverage continued through 2025, but study authors recognize a need for further and more consistent coverage.

High pulse pressure and low education levels significantly worsen amyloid-related cognitive decline in adults aged 90 years and older.

Relatively few adults report discussing vascular health with a health care provider despite the prevalence of vascular disease in the US.

As more people are exposed to rabid or possibly rabid animals, the CDC advises anyone bit or scratched by an animal to seek care immediately.

Adults with chronic cough exhibited significant reductions in GMV across multiple brain regions when compared with a healthy control group.

High serum glial fibrillary acidic protein levels indicate an increased risk for progression independent of relapse activity in multiple sclerosis.

A recent study of people with autism spectrum disorder and covered by Medicaid found that people with autism have a shorter life expectancy.

A novel speech-based model successfully distinguishes between nonfluent, logopenic, and semantic variants of primary progressive aphasia.

The FDA granted Priority Review to satralizumab for MOGAD, a rare CNS demyelinating disease, backed by phase 3 METEOROID trial data showing a 68% risk reduction.